NCT Number: NCT00032942
Lofexidine for Opiate Withdrawal - 1
The purpose of this study is to evaluate lofexidine for opiate withdrawal.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–99 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
UCLA Medical Center, Los Angeles, California, United States
About this study
An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male or female as least 18 yrs of age & above with a current dependence on heroin, morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed informed consent; females using appropriate birth control method.
Exclusion criteria
Additional criteria available during screening at the site
Treatment and study plan
Primary outcomes
-
Opiate withdrawal symptoms
-
Potential Abuse Liability
Sponsors and collaborators
Lead sponsor
National Institute on Drug Abuse (NIDA)
Nih
Collaborators
- Britannia Pharmaceuticals Ltd.
Registry information
Official study title
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal
Important dates
- Study start
- 2001
- Primary completion
- 2004
- First posted
- Apr 8, 2002
- Registry last updated
- Jan 12, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Buprenorphine Group Medical Visits in Primary Care
NCT02526212
Chemically-Induced Disorders, Mental Disorders
The Bronx, New York, United States
View Trial DetailsAn Innovative Intervention for OUD Treatment
NCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsTau PET Imaging in Opioid Use Disorder
NCT05651516
Brain Diseases, Central Nervous System Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsPreventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR
NCT05380440
Amphetamine-Related Disorders, Chemically-Induced Disorders
Eugene, Oregon, United States
View Trial Details